Product Images Capecitabine

Each tablet of Capecitabine, USP contains 5mg of the active ingredient. It is advised to store the tablets in a tightly closed container at a temperature of 20° to 25°C (68° to 77°F). Capecitabine is a cytotoxic agent used for cancer treatment. The usual dosage should be referred to from the package insert. The tablets are made in yellow color using a FOSC Yellow No. 6 additive. The package consists of 60 tablets and it is produced by Hikma Pharmaceuticals.*

Capecitabine Tablets, USP contain 500mg of the active ingredient. The tablets should be dispensed in tightly sealed containers as defined by USP INF. They should be stored at controlled room temperature and kept tightly closed. The usual dosage recommendation and prescribing information can be found in the accompanying insert. These tablets contain FDAC Yellow No. 6 as a color additive. Capecitabine is a cytotoxic agent used to treat certain types of cancer. This product is distributed by Hikma Pharmaceuticals USA Inc.*

available*

This text appears to be describing different doses and regimens of chemotherapy treatment for cancer. The Mayo Regimen (5-FU + Leucovorin) and Capecitabine (1250mg/m? twice daily) are mentioned. The chart shows estimated probabilities over a range of days. It is possible that this information is being used to help doctors determine the best treatment plan for their patients.*

This text appears to be a graph or a chart that displays the estimated probability of a certain event or outcome over time (measured in days) for a group of patients who received specific medication. The medication includes Docetaxel and Capecitabine, and the dosages are specified in milligrams per square meter of body surface area and frequency. Without further context, it is unclear what the event or outcome being measured is, or what the significance of the probability estimates may be.*

The text seems to be presenting data related to a study comparing the effectiveness of two drugs named 5FU+Leucovorin and Capecitabine, in terms of survival rate, on individuals undergoing some form of treatment. The results of the study have been presented in a tabular form with months since randomization on the x-axis and survival rate on the y-axis. The different treatment groups are also mentioned.*